Ann Tsukamoto

Tsukamoto’s research and contributions in the medical field have led to groundbreaking advancements in stem cell research, especially in understanding the blood systems of cancer patients. Her work has shown potential treatments for cancers and neurological disorders, for which there were previously thought to be none.

Career

Ann Tsukamoto was born in California on July 6, 1952. She completed her bachelor's degree at the University of California San Diego and her Ph.D. in immunology and microbiology at the University of California Los Angeles. Tsukamoto did most of her postdoctoral work at the University of California, San Francisco. Here, she worked on the wnt-1 gene and developed a transgenic model for breast cancer. Wnt-1 was later discovered to be a key player in the stem cell self-renewal pathway. She joined the biotech company SyStemix from 1989 to 1997, where she co-discovered the human hematopoietic stem cell (hHSC) and played a leading role in the launch of the clinical research program for this cell. The purified hHSC was shown to be cancer-free when isolated from the cancer-contaminated hematopoietic mobilized blood of patients with disseminated cancer, and it successfully regenerated the patients' blood-forming system after myeloablative chemotherapy. Tsukamoto joined StemCells Inc. in 1998, where she has held several leadership roles overseeing the isolation and application of human neural and liver stem cells for various diseases. She led the scientific team that discovered the human central nervous system stem cell and identified a second candidate stem cell for the liver. Under her guidance, the human neural stem cell transitioned into early clinical development for all three components of the central nervous system: the brain, spinal cord, and eye. The biological potential and activity of these cells were demonstrated in some of the patients, mirroring the results observed in preclinical rodent studies.

As of 2017, Tsukamoto is an inventor on seven issued United States patents, six of which are related to the human hematopoietic stem cell. By 2021, she had reached a total of 13 patents. Aside from her accomplishments in patent applications and grants, in 2023 she was awarded with the Changemaker Award from her alma mater (University of California San Diego) for her breakthrough in isolating blood stem cells. The work of Ann Tsukamoto has been of immense value to the field of regenerative medicine, particularly in the treatment and research of neurodegenerative diseases. Her research on human neural stem cells has resulted in potential therapeutic treatments for conditions such as spinal cord injury, Alzheimer's disease, and Parkinson's disease. Isolation of these stem cells has been a platform for further clinical research, testing their ability to repair and regenerate damaged neural tissues. Besides her contribution to hematopoietic and neural stem cell biology, her research and work has influenced advancements in gene therapy and tissue engineering, demonstrating the far-reaching nature of her scientific contribution.

Tsukamoto has been a firm advocate for diversity in STEM, having mentored early-career researchers and lobbying for programs to integrate more women into the biotechnology industry. She has given talks regarding determination and collaboration in scientific inquiry, particularly among women and other minority groups within the discipline. Through public debate and mentorship initiatives, she continues to inspire upcoming generations of young female scientists to push beyond the limits of medical discovery. Her dedication to training the next generation of scientists, along with her significant contributions to stem cell research, has ensured her place in the world as a biotechnology pioneer.